Department of Public Health and Primary Care, KU Leuven Campus Kulak, Kortrijk, Belgium.
R&D Department, InfYnity Biomarkers, Lyon, France.
PLoS One. 2022 Sep 29;17(9):e0274553. doi: 10.1371/journal.pone.0274553. eCollection 2022.
Collecting information on sustainability of immune responses after infection or vaccination is crucial to inform medical decision-making and vaccination strategies. Data on how long-lasting antibodies against SARS-COV-2 could provide a humoral and protective immunity and prevent reinfection with SARS-CoV-2 or its variants is particularly valuable. This study presents a novel method to quantitatively measure and monitor the diversity of SARS-CoV-2 specific antibody profiles over time.
Serum samples from two groups were used in this study: Samples from 20 naturally infected subjects (followed for up to 1 year) and samples from 83 subjects vaccinated with one or two doses of the Pfizer BioNtech vaccine (BNT162b2/BNT162b2) (followed for up to 6 months). The Multi-SARS-CoV-2 assay, a multiparameter serology test developed for the serological confirmation of past-infections, was used to determine the reactivity of six different SARS-CoV-2 antigens. For each subject sample, 3 dilutions (1/50, 1/400 and 1/3200) were defined as an optimal set over the six antigens and their respective linear ranges. This allowed accurate quantification of the corresponding six antibodies. Nonlinear mixed-effects modelling was applied to convert intensity readings from 3 determined dilutions to a single quantification value for each antibody.
Median half-life for the 20 naturally infected vs 74 vaccinated subjects (two doses) was 120 vs 50 days for RBD, 127 vs 53 days for S1 and 187 vs 86 days for S2 antibodies respectively.
The newly proposed method, based on a series of a limited number of dilutions, can convert a conventional qualitative assay into a quantitative assay. This conversion helps define the sustainability of specific immune responses against each relevant viral antigen and can help in defining the protection characteristics after an infection or a vaccination.
收集感染或接种疫苗后免疫反应可持续性的信息对于为医疗决策和疫苗接种策略提供信息至关重要。关于针对 SARS-CoV-2 的抗体能持续多长时间,以及其能否提供体液和保护性免疫并预防再次感染 SARS-CoV-2 或其变体的数据尤其有价值。本研究提出了一种定量测量和监测 SARS-CoV-2 特异性抗体谱随时间变化的新方法。
本研究使用了两组血清样本:20 名自然感染受试者(随访时间长达 1 年)和 83 名接受 1 或 2 剂辉瑞 BioNtech 疫苗(BNT162b2/BNT162b2)接种的受试者(随访时间长达 6 个月)。使用多 SARS-CoV-2 检测试剂盒(一种用于血清学确认既往感染的多参数血清学检测试剂盒)来确定 6 种不同 SARS-CoV-2 抗原的反应性。对于每个受试者样本,确定了 6 种抗原及其各自的线性范围的 3 个稀释度(1/50、1/400 和 1/3200)作为最佳设置。这允许对相应的 6 种抗体进行准确的定量。应用非线性混合效应模型将 3 个确定的稀释度的强度读数转换为每个抗体的单个定量值。
20 名自然感染受试者与 74 名接种疫苗(两剂)受试者的 RBD、S1 和 S2 抗体的中位数半衰期分别为 120 天和 50 天、127 天和 53 天、187 天和 86 天。
基于一系列有限数量的稀释度的新提出的方法可以将常规定性检测转化为定量检测。这种转换有助于定义针对每种相关病毒抗原的特异性免疫反应的可持续性,并有助于在感染或接种疫苗后定义保护特征。